{"name":"Institut de Cancérologie de la Loire","slug":"institut-de-canc-rologie-de-la-loire","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9ueGFNNjV6UENJa3JqRTI5VkFHQXVhZFJPT2wwdEZLVlFYOG9Ob0EtVUJmMGpRUlhubEsyVDNJNUNxak9ocGN5R08xRk5NaGhXbkF0dUtiMXlVVlFXU0U4T1RyTXFDeHNZLVVVLWJ3?oc=5","date":"2025-01-14","type":"pipeline","source":"ERS - European Respiratory Society","summary":"Cancer risk in patients with sleep apnoea following adherent 5-year CPAP therapy - ERS - European Respiratory Society","headline":"Cancer risk in patients with sleep apnoea following adherent 5-year CPAP therapy - ERS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5DRzhuc2QzR09OLXhnR1dQYUItTExCU2dUY3VCdE9YXy1EMURjTFFTTVRYWFNqLWo0RTVNV2pBSkF3MzdrODlUaFB6cU9DTmNINjlsdE9xNzljcWlURE53?oc=5","date":"2024-07-16","type":"trial","source":"nature.com","summary":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial - nature.com","headline":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clini","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE0xSVBjQXg4eTJvUlh6NkV0eVpRaWZNSU5PZ3hxajRiQklieUhSX3FRTnVmSGFNQzJJS09aMndoNTg1YVdmclJzZUhIc3VrRGk3T3ZrVHRuem4xZ1JYX1cw?oc=5","date":"2023-08-18","type":"pipeline","source":"nature.com","summary":"Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program - nature.com","headline":"Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the Fre","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}